Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?

Valneva SE Sponsored ADR (NASDAQ:VALN) gapped down before the market opened on Monday. The stock had previously closed at $5.91, but opened at $5.53. Valneva shares last traded at $5.47, with a volume of 1,748 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. TD Cowen began coverage on Valneva in a research report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research note on Monday, September 14th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $9.30.

Valneva Price Performance

The stock’s 50-day simple moving average is $6.35 and its 200 day simple moving average is $5.82. The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04. The company has a market cap of $521.42 million, a price-to-earnings ratio of -2.60 and a beta of 1.53.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. The firm had revenue of $39.37 million for the quarter, compared to analysts’ expectations of $44.17 million. On average, equities research analysts anticipate that Valneva SE Sponsored ADR will post -1.27 EPS for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.